Agonists

GLP-1 and GIP Agonists: The Key to Revolutionizing Psychiatric Treatment?

by

Toronto, Canada – The use of incretin therapy drugs like GLP-1 and GIP receptor agonists is gaining traction as a potential treatment for a wide range of chronic diseases, including cardiometabolic, renal, hepatic, obesity, and even psychiatric conditions. During the American Psychiatric Association (APA) 2024 Annual Meeting, Dr. Roger S. McIntyre, a professor of psychiatry and pharmacology at the University of Toronto, discussed the promising prospects of using GLP-1 and GIP receptor agonists to treat …

Read more

Diabetes Drug Breakthrough: New Research Suggests GLP-1R Agonists Could Slow Parkinson’s Progression

by

Paris, France – A recent study conducted in Paris, France suggests that a drug similar to those used in “skinny jabs” could potentially slow down the progression of symptoms associated with Parkinson’s disease. Parkinson’s is a neurodegenerative condition that affects over 10 million people globally, resulting in the gradual loss of nerve cells in the brain and leading to movement difficulties, balance issues, and memory problems. While current treatments aim to manage symptoms, there is …

Read more